- Entry
- $94.23
- Final
- $97.94 +3.9%
- Target
- —
- Score
- +0.39
BillionToOne - $BLLN - Their flagship prenatal test screens for genetic conditions like sickle cell and cystic fibrosis from a simple maternal blood draw, replacing invasive procedures like amniocentesis. The same platform now powers their oncology business, where liquid biopsy tests detect cancer DNA in the bloodstream to guide treatment decisions without a tissue biopsy. 3 things have me drooling over this stock. The founder - Oguzhan Atay, Princeton valedictorian, Stanford PhD in Systems Biology, built the core technology himself. …
— ORIGINAL POST ·
Billion To One
· r/wallstreetbets
· May 13, 2026